[Clinical experiences with a new topical steroid].
44 patients have been treated in a double-blind trial with Desoximetason (0.25%) and with Betamethasone-valerate (0.1%). It was a randomised left-right comparative trial, and Desoximetason was significantly better than the comparative drug in all observation periods (except the period 1-2 days). Desoximetason has also been tested on 280 patients in an open trial, showing good efficacy and good tolerance.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000031:analogs & derivatives*; D001624:Betamethasone Valerate / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003872:Dermatitis / Q000188:drug therapy; D003907:Dexamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D004485:Eczema / Q000188:drug therapy; D006801:Humans; D007223:Infant; D008875:Middle Aged; D009450:Neurodermatitis / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy
D003907:Dexamethasone; D001623:Betamethasone; D001624:Betamethasone Valerate
Klinische Erfahrungen mit einem neuen Lokalsteroid